牛牛AI助理已提取核心訊息
On December 31, 2023, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G with the United States Securities and Exchange Commission, disclosing a 9.99% ownership stake in 180 Life Sciences Corp. The filing indicates that Armistice Capital, LLC and Steven Boyd collectively hold 1,112,480 shares of common stock in the company. The shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC acts as the investment manager, granting it voting and investment power over the securities. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of 180 Life Sciences Corp. The percentage ownership is based on 11,135,940 shares outstanding as of December 26, 2023, as reported in the company's Schedule 14A filed with the SEC. The filing was completed on February 14, 2024.
On December 31, 2023, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G with the United States Securities and Exchange Commission, disclosing a 9.99% ownership stake in 180 Life Sciences Corp. The filing indicates that Armistice Capital, LLC and Steven Boyd collectively hold 1,112,480 shares of common stock in the company. The shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC acts as the investment manager, granting it voting and investment power over the securities. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of 180 Life Sciences Corp. The percentage ownership is based on 11,135,940 shares outstanding as of December 26, 2023, as reported in the company's Schedule 14A filed with the SEC. The filing was completed on February 14, 2024.
2023年12月31日，停戰資本有限責任公司及其管理成員史蒂芬·博伊德向美國證券交易委員會提交了附表13G，披露了180生命科學公司9.99％的所有權。該文件顯示，停戰資本有限責任公司和史蒂芬·博伊德共持有該公司1,112,480股普通股。這些股票由停戰資本主基金有限公司持有，Armistice Capital, LLC擔任該公司的投資經理，賦予其對證券的投票權和投資權。該文件稱，這些股份是在正常業務過程中收購的，不是爲了改變或影響180生命科學公司的控制權。根據該公司向美國證券交易委員會提交的附表14A所述，所有權百分比基於截至2023年12月26日的11,135,940股已發行股票。該申請於 2024 年 2 月 14 日完成。
2023年12月31日，停戰資本有限責任公司及其管理成員史蒂芬·博伊德向美國證券交易委員會提交了附表13G，披露了180生命科學公司9.99％的所有權。該文件顯示，停戰資本有限責任公司和史蒂芬·博伊德共持有該公司1,112,480股普通股。這些股票由停戰資本主基金有限公司持有，Armistice Capital, LLC擔任該公司的投資經理，賦予其對證券的投票權和投資權。該文件稱，這些股份是在正常業務過程中收購的，不是爲了改變或影響180生命科學公司的控制權。根據該公司向美國證券交易委員會提交的附表14A所述，所有權百分比基於截至2023年12月26日的11,135,940股已發行股票。該申請於 2024 年 2 月 14 日完成。
有用
沒用
